皮马万塞林的安全性概况:来自3b期临床试验的见解
1Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA.
Journal of Alzheimer's disease : JAD
|May 24, 2024
概括
皮马万塞林在治疗神经退行性疾病 (NDD) 的老年人神经精神病症状方面表现有前途. 这项研究强调了与较老的抗精神病药物相比,它的安全性,尽管需要进一步的研究.
科学领域:
- 老年病的医生 老年病的医生
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
背景情况:
- 神经精神病症状在患有神经退行性疾病 (NDD) 的老年人中很常见.
- 抗精神病疗法已经发展,寻求提高安全性.
- 皮马万塞林代表了管理这些症状的新选择.
研究的目的:
- 评估pimavanserin在患有各种NDD的老年人中的安全性.
- 为了将皮马万塞林的安全性和疗效与历史抗精神病治疗相对应.
- 为了提供一个细微的临床视角,pimavanserin的优势.
主要方法:
- 在患有NDD的患者中对皮马万塞林进行3b期研究的分析.
- 在抗精神病治疗的演变过程中,评论审查研究结果.
- 皮马万塞林的个人资料与历史数据和监管里程碑的比较.
主要成果:
- 阿尔瓦和其他人. 这项研究为pimavanserin在NDD患者中的安全性提供了新的数据.
- 皮马万塞林在较旧的抗精神病治疗中提供了潜在的优势.
- 在不断发展的抗精神病治疗的背景下,研究了该药物的安全性.
结论:
- 皮马万塞林在患有NDD的老年人中表现出对神经精神症状的有利安全概况.
- 为了充分了解皮马万塞林的治疗潜力,需要进一步的研究.
- 临床医生可以考虑pimavanserin作为传统抗精神病药物的更安全替代品.
更多相关视频
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
32.2K
10:26A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.2K
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
124
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
124
